利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.031 秒)

    Peptide (VIRIP) which inhibits a circulating virus in humans and the use thereof
    6.
    发明授权
    Peptide (VIRIP) which inhibits a circulating virus in humans and the use thereof 失效
    抑制人类循环病毒的肽（VIRIP）及其用途

    公开(公告)号：US07037896B1

    公开(公告)日：2006-05-02

    申请号：US10111427

    申请日：2000-11-08

    申请人： Frank Kirchhoff ,  Jan Münch ,  Ludger Ständker ,  Wolf-Georg Forssmann

    发明人： Frank Kirchhoff ,  Jan Münch ,  Ludger Ständker ,  Wolf-Georg Forssmann

    IPC分类号： A61K38/16 ,  C07K7/08 ,  C07K2/00 ,  A61K38/00 ,  A61K38/02

    CPC分类号： C07K7/08 ,  A61K38/00

    摘要： A peptide having the following amino acid sequence: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, polyethylene glycol (PEG) modified, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of VIRIP; wherein Z1 and Z2 are independently a sequence of from 0 to 10 amino acid residues, and if Z1 or Z2=zero amino acid residues, then Z1=H and/or Z2=COOH.

    摘要翻译： 具有以下氨基酸序列的肽：<？in-line-formula description =“In-line Formulas”end =“lead”？> Z 1 -leAIPMSIPPEVKFNKPFVF-Z 2 （VIRIP）<？in-line-formula description =“In-line Formulas”end =“tail”？>及其生物活性片段和/或变体和/或衍生物，特别是酰胺化，乙酰化，硫酸化，聚乙二醇 （PEG）修饰的，磷酸化和/或糖基化衍生物，以及可通过多重合成获得的具有VIRIP生物学活性的肽; 其中Z 1和Z 2独立地是0至10个氨基酸残基的序列，并且如果Z 1或Z 2 0个氨基酸残基，则Z 1 = H和/或Z 2 = COOH。

    Peptides and their use for the treatment of HIV infections
    7.
    发明授权
    Peptides and their use for the treatment of HIV infections 失效

    公开(公告)号：US07655629B2

    公开(公告)日：2010-02-02

    申请号：US10539627

    申请日：2003-12-19

    申请人： Knut Adermann ,  Frank Kirchhoff ,  Jan Münch ,  Axel Schulz

    发明人： Knut Adermann ,  Frank Kirchhoff ,  Jan Münch ,  Axel Schulz

    IPC分类号： A61K38/00 ,  A61K38/04 ,  A61K51/00 ,  A61M36/14 ,  C12Q1/70

    CPC分类号： C07K7/08

    摘要： The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13 is an amino acid with a hydrophobic or an aromatic side chain; X14 is an amino acid with a hydrophobic or an aromatic side chain; X15 is a phenylalanine or deletion; Z1 is NH2 or a sequence of 1 to 10 amino acid residues; Z2 is COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the provisio that (a) if X12 is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X13, X14 and X15 are phenylalanine, valine and phenylalanine respectively; and/or (b) if X12 is phenylalanine, than X13, X14 and X15 are valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide.